“SynBIA formed to address the emergence of synthetic biology industry ... - News-Medical.Net” plus 4 more

---

• SynBIA formed to address the emergence of synthetic biology industry ... - News-Medical.Net
• Biology of Emergent Salmonella Exposed: Deadly Bug Targets Vulnerable ... - Science Daily
• InSea2(TM) new human study supports its role as the next generation of ... - NPI center
• Discovery of the Jekyll-and-Hyde factors in 'coral bleaching' - EurekAlert
• RNA on the Move - Science Daily

This content has passed through fivefilters.org.

SynBIA formed to address the emergence of synthetic biology industry ... - News-Medical.Net Posted: 02 Dec 2009 01:58 AM PST To address the emergence of the synthetic biology industry and to promote its potential, a group of individuals and companies announced the formation of the Synthetic Biology Industry Association (SynBIA) in Cambridge, Massachusetts last week. The goal of the association is to provide a forum for individuals and commercial interests to discuss the new industry, address its opportunities and its challenges, and advocate for its development. Founding members include representatives of febit, GENEART, Ginkgo BioWorks, Biosearch Technologies and Sutro Biopharma. The association will serve as the trade association home for a diverse group of companies and individuals involved in synthetic biology development, including companies involved in gene synthesis, pharmaceutical development, energy development, and pollution control. The goal is to responsibly join the public discussion and promote development. Among the more specific goals of SynBIA is an informed discussion about the risks and rewards of development. This includes participation in the discussion of dual use and in the current discussion regarding voluntary screening obligations (codes of conduct). Association members are active participants in meetings with the FBI, the National Academy of Sciences and the Association for the Advancement of Science relating to the developing synthetic biology field. Founding Chairman JD Kittle noted, "The industry has strong potential to be a part of the solution to problems in the world's health, energy and environmental arenas. SynBIA plans to be a part of the discussion advocating for increased funding to enhance participation in these areas." Founding Board member, Mark Waxman of Foley & Lardner, also pointed out that with the increasing visibility, IP portfolios, and transaction volume, there is a developing need for an association to address industry issues. Founding board member Frank Notka of GENEART complemented, "These industry issues have to be tackled with regard to the international character and the resulting challenges for transnational arrangements. SynBIA will through its international composition and orientation contribute to this scheme." The SynBIA will have a collaborative relationship with the International Association of Synthetic Biology (IASB) and, through that relationship, seek to enhance international relationships developing in this field. The IASB is the international platform for synthetic biology as a field of activity. Cord F. Staehler, CEO and President of febit who is a founder and board member of both SynBIA and IASB stated, "We welcome this new addition, as it is important to have an international approach to this new and exciting industry." SOURCE Synthetic Biology Industry Association (SynBIA) This content has passed through fivefilters.org.
Biology of Emergent Salmonella Exposed: Deadly Bug Targets Vulnerable ... - Science Daily Posted: 02 Dec 2009 08:03 AM PST [fivefilters.org: unable to retrieve full-text content] This type of Salmonella bug normally causes diarrhoea and is rarely fatal. The new strain infects vulnerable children and adults in many regions of sub-Saharan Africa leading to death in up to one in four cases. The new genome work, a collaboration ...
InSea2(TM) new human study supports its role as the next generation of ... - NPI center Posted: 02 Dec 2009 07:06 AM PST	InSea2(TM) new human study supports its role as the next generation of Carb/Starch control ingredients 2009-12-02 - innoVactiv inc. Rimouski (Quebec), December 1st, 2009 – innoVactiv inc., a Canadian company dedicated to developing science-based ingredients, is pleased to report that InSea2™ produced statistically significant results in a recently completed human clinical trial. The aim of the study was to test the ability of InSea2™ to lower serum glucose levels and insulin response versus placebo that follow ingestion of a test food. Given the positive results from the study, InSea2™ represents a new breed of carb/starch control ingredients in the dietary supplement market and offers consumers a tool that can provide unsurpassed control over the normal blood sugar and insulin response to a meal. In a randomized crossover, double-blinded, placebo-controlled human clinical trial led by the Institute of Nutraceuticals and Functional Foods of Laval University (Quebec, Canada), InSea2™ (at a single dose of 500 mg) induced a statistically significant 44% decrease in the normal glycemic response that follows ingestion of a standardized meal (white bread, P=0.046) in twenty-three healthy volunteers. InSea2™ also induced a 22% reduction in initial insulin production (P=0.045) and an overall 5.9% reduction in the area under the curve of the insulin response (P=0.031). Even more interesting was the fact that InSea2™ improved insulin sensitivity by 6.9% (Cederholm index, P=0.047) after a single use of the product. The results of this study will be presented at the Experimental Biology meeting in Anaheim, CA, April 24-28, 2010. "We are very excited by these results, confirming the efficacy of InSea2™ in humans. The fact that we reached statistically significant results at low dosage levels is encouraging, especially from a pure science perspective. The study demonstrates that InSea2™ and its dual mechanism of action may offer a superior efficacy compared to other ingredients that block only one of the two enzymes involved in carb digestion" says Jocelyn Bérubé, Scientific Director, Health & Nutrition at innoVactiv. InSea2™ is the only safe and natural ingredient that offers a dual mechanism of action targeting carbohydrate digestion. It works by inhibiting both α-amylase and α-glucosidase enzymes, a process which may lead to a more effective blockage than simple α-amylase or α-glucosidase inhibitors currently on the market. Alpha-amylase and α-glucosidase are respectively known for breaking down complex starches into smaller oligosaccharides, and for digesting oligosaccharides and disaccharides such as table sugar into simple glucose for absorption. "We could not be happier with the results of this study, which provides substantial evidence on the efficacy of InSea2™ in improving the management of blood sugar. These new human data on InSea2™ really bring innoVactiv at the forefront of science-based ingredients suppliers. This fits with our strategic vision of nurturing long-term partnerships with companies that use scientifically proven ingredients to drive new product development. Our goal is to ultimately provide the consumer with a top-shelf product that helps safely improve their health and quality of life," added Patrice Dionne, Chief Executive Officer of innoVactiv. About innoVactiv innoVactiv's mission is to develop and supply innovative ingredients whose efficacy and safety have been scientifically demonstrated. In addition to its two newest nutraceutical active ingredients, InSea2™ and PeptiBal™, innoVactiv has developed a line of 16 cosmeceutical ingredients and holds a strong development pipeline of additional ingredients that will offer solutions for maintaining optimal human health. For more information on innoVactiv, please contact Patrice Dionne, Chief Executive Officer: pdionne@innovactiv.com or visit www.innovactiv.com. Share on
Discovery of the Jekyll-and-Hyde factors in 'coral bleaching' - EurekAlert Posted: 02 Dec 2009 08:03 AM PST Public release date: 2-Dec-2009 [ | E-mail | Share ] Contact: Michael Bernstein m_bernstein@acs.org 202-872-6042 American Chemical Society Scientists are reporting the first identification of substances involved in the Jekyll-and-Hyde transformation that changes harmless marine bacteria into killers that cause "coral bleaching." Their study appears in ACS' Environmental Science & Technology, a semi-monthly journal. Dan Bearden and colleagues note that bleaching already has destroyed up to 30 percent of the world's coral reefs, and scientists are searching for ways to slow or stop the damage. One known culprit is an ocean-dwelling bacterium, Vibrio coralliilyticus (V. coralliilyticus) that chokes-off corals' energy supply and kills these shell-clad marine animals. At lower temperatures, the bacteria are harmless to coral. But at warmer temperatures (above 75 degrees Fahrenheit) the bacteria become virulent and can kill coral. The new study reports identification of three chemicals betaine, glutamate, and succinate that V. coralliilyticus produces in warmer water and are involved in the transformation. The discovery opens the door to understanding the biology involved in the complex interactions between corals and bacteria and unraveling the mystery of coral bleaching, the scientists indicated. ARTICLE FOR IMMEDIATE RELEASE "NMR-Based Microbial Metabolomics and the Temperature-Dependent Coral Pathogen Vibrio coralliilyticus" DOWNLOAD FULL TEXT ARTICLE http://pubs.acs.org/stoken/presspac/presspac/full/10.1021/es901675w CONTACT: Daniel Bearden, Ph.D. National Institute of Standards and Technology Hollings Marine Laboratory Charleston, S.C. 29412 Phone: (843)-762-8865 Fax: (843)-762-8742 Email: dan.bearden@nist.gov [ | E-mail | Share ]   This content has passed through fivefilters.org.
RNA on the Move - Science Daily Posted: 02 Dec 2009 07:06 AM PST ScienceDaily (Dec. 3, 2009) — In the fruit fly Drosophila, oskar mRNA, which is involved in defining the animal's body axes, is produced in the nuclei of nurse cells neighbouring the oocyte, and must be transported to the oocyte and along its entire length before being translated into protein. Scientists in the group of Anne Ephrussi at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, have visualized the molecular mechanism that underlies this localisation process. In a study published in Cell, they showed for the first time that, upon export from the nucleus of nurse cells into the cytosol -- the semifluid that surrounds a cell's nucleus -RNA particles recruit two motor proteins, kinesin and dynein, which transport the RNA to its final location in the oocyte. By combining immunofluorescence with electron microscopy imaging, the EMBL scientists were able to discriminate where different molecules critical for oskar mRNA transport are recruited, thus defining a hierarchy of RNA particle assembly. These findings not only increase our understanding of development, but could also shed light on processes underlying the function of dendrites and axons in neurons, and synaptic plasticity -- which is implicated in learning and memory formation -- as these also entail the transport and localised translation of RNA. Story Source: Adapted from materials provided by European Molecular Biology Laboratory (EMBL). Journal Reference: Trucco et al. Assembly of Endogenous oskar mRNA Particles for Motor-Dependent Transport in the Drosophila Oocyte. Cell, 2009; 139 (5): 983 DOI: 10.1016/j.cell.2009.10.012 Note: If no author is given, the source is cited instead. This content has passed through fivefilters.org.

You are subscribed to email updates from Biology - Bing News To stop receiving these emails, you may unsubscribe now.	Email delivery powered by Google
Google Inc., 20 West Kinzie, Chicago IL USA 60610